Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27448869 | 0.97 | BRD4 (0.52) | BRD4CREBBPIDO1ACHEDRD3 | |
| SCHEMBL29978110 | 0.82 | PLAU (0.56) | PLAUTSHR | |
| SCHEMBL30147984 | 0.82 | BRD4 (0.41) | BRD4CREBBPIDO1ACHEDRD3 | |
| SCHEMBL15147099 | 0.82 | PLAU (0.56) | PLAUTSHR | |
| SCHEMBL598142 | 0.82 | PLAU (0.56) | PLAUTSHR | |
| SCHEMBL31236843 | 0.81 | IDO1 (0.46) | IDO1ACHEDRD3PLAUTSHR | |
| SCHEMBL31236844 | 0.81 | IDO1 (0.46) | IDO1ACHEDRD3PLAUTSHR | |
| SCHEMBL11863282 | 0.80 | PLAU (0.54) | PLAU | |
| SCHEMBL15967875 | 0.78 | CYP3A4 (0.48) | BRD4CREBBPTSHR | |
| SCHEMBL15888992 | 0.78 | TSHR (0.50) | IDO1PLAUTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122052-A | Ink composition | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-111432851-A | Use of volatile ingredients to limit or eliminate perception of malodour | 弗门尼舍有限公司 | 2020-07-17 | — | — | CN | claimed |
| CN-106543078-A | A kind of preparation method of quinoline | 中国科学院兰州化学物理研究所苏州研究院 | 2017-03-29 | — | — | CN | claimed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | claimed |
| CN-103980151-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2014-08-13 | — | — | CN | claimed |
| CN-102516115-A | Novel compounds as antagonists or inverse agonists at opioid receptors | SMITHKLINE BEECHAM CORP | 2012-06-27 | — | — | CN | claimed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | claimed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | claimed |
| JP-4347906-B2 | — | — | 2009-10-21 | — | — | JP | claimed |
| CN-101522614-A | Novel compounds as antagonists or inverse agonists of opioid receptors | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | CN | claimed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | claimed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | claimed |
| US-6265228-B1 | REACTING AT LEAST ONE STARTING COMPOUND ATTACHED TO SOLID SUPPORT WITH SPECIFIC PRIMARY OR SECONDARY AMINE IN PRESENCE OF CARBOXYLIC ACID ACTIVATING AGENT TO PRODUCE DIACETOXY AMIDES, THEN TREATING WITH HYDRAZINE TO PRODUCE LIBRARY | PHARMACOPEIA, INC. | 2001-07-24 | — | — | US | claimed |
| US-6255120-B1 | HYDROXYAMIDES ATTACHED TO SOLID SUPPORT | PHARMACOPEIA, INC. | 2001-07-03 | — | — | US | claimed |
| US-6087137-A | PREPARING OPTICALLY ACTIVE COMPOUNDS FOR USE AS CHEMICAL INTERMEDIATES IN SYNTHESIS OF DRUGS AND AGRICULTURAL CHEMICALS ESPECIALLY ENZYME INHIBITORS TARGETED TO HUMAN IMMUNODEFICIENCY VIRUS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | claimed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | claimed |
| US-5976894-A | FOR SCREENING BIOASSAYS TO DISCOVER BIOLOGICALLY ACTIVE MEMBERS | PHARMACOPEIA, INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0828848-A1 | PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE | ZENECA LIMITED (GB) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037628-A1 | PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE | ZENECA LIMITED (GB) | 1996-11-28 | — | — | WO | claimed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | BRD4 530/4885CREBBP 569/4885IDO1 1281/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | BRD4 1673/4885CREBBP 905/4885IDO1 1130/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | BRD4 1419/4885CREBBP 907/4885IDO1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.